Cenicriviroc, a CCR2/CCR5 inhibitor, is being used in clinical trials for the treatment of liver fibrosis in nonalcoholic steatohepatitis patients47. Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.